# Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-of-empagliflozin-versus-canagliflozin-dapagliflozin-or/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Odette S. Reifsnider,Anuraag R Kansal,Pranav Gandhi,Lael Cragin,Sarah Brand,Egon Pfarr,Kyle Fahrbach,Anastasia Ustyugova |
| Citations | 27 |
| DOI | 10.1136/bmjdrc-2020-001313 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://drc.bmj.com/content/bmjdrc/9/1/e001313.full.pdf |
| OpenAlex ID | https://openalex.org/W3158572228 |
| PMID | 33941549 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Pranav Gandhi](https://scholariq.org/researchers/pranav-gandhi/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.